LGND — Ligand Pharmaceuticals Incorporated

Summary of Ligand Pharmaceuticals (LGND) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full-Year 2025 Performance:
  • Total GAAP revenue: $268 million, up from $167 million in 2024.
  • Core revenue (excluding Pelthos sale gain): $240 million, reflecting 43% growth year-over-year.
  • Royalty revenue: $161 million, a 48% increase, driven by FILSPARI, Ohtuvayre, CAPVAXIVE, and Qarziba.
  • Adjusted EPS: $8.13, up 42% year-over-year.
• Q4 2025 Performance:
  • Total revenue: $59.7 million, a 39% increase year-over-year.
  • Royalty revenue: $50.5 million, up 45% year-over-year.
  • Adjusted net income: $42.7 million, or $2.02 per diluted share, compared to $1.27 in Q4 2024.
  • Strong balance sheet with $734 million in cash and over $1 billion in deployable capital.

2. Strategic Updates and Business Highlights

• Portfolio Performance: Strong performance from FILSPARI, with U.S. net sales of $103 million in Q4, and Ohtuvayre achieving approximately $500 million in its first full year.
• New Developments: Positive Phase 3 trial results for Palvella's QTORIN rapamycin, expected to be the first FDA-approved treatment for microcystic lymphatic malformations (mLM).
• Portfolio Management Strategy: Implementation of a systematic approach to enhance partner communication and identify new investment opportunities.
• Expansion in Royalty Financing: Increased demand for royalty capital, with Ligand positioned to capitalize on this growing market.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • Adjusted EPS expected to be between $8 to $9 per share.
  • Royalty revenue forecasted at $200 million to $225 million, representing a 32% growth at the midpoint.
  • Total revenue projected between $245 million to $285 million.
  • Anticipated continued growth from FILSPARI, Ohtuvayre, CAPVAXIVE, and ZELSUVMI.

4. Bad News, Challenges, or Points of Concern

• Regulatory Delays: The FDA extended the review timeline for FILSPARI's sNDA for FSGS, which may impact short-term revenue expectations, with a modest $4 million contribution assumed for 2026.
• Market Competition: The competitive landscape for treatments in the same therapeutic areas remains a concern, particularly for FILSPARI and other pipeline products.

5. Notable Q&A Insights

• Clinical Updates: Management highlighted an active late-stage pipeline with multiple upcoming updates, including for Qarziba and Tzield.
• Monetizing Older Assets: Ligand is actively exploring opportunities to revitalize older assets, with several initiatives underway.
• Market Opportunities: Tzield's potential market is significant, but the low royalty rate could limit Ligand's revenue from this asset.
• Royalty Financing Trends: Management noted a robust pipeline of opportunities in royalty financing, indicating strong demand despite broader market conditions.

Overall, Ligand's Q4 2025 earnings call reflected strong financial performance and strategic positioning, with a focus on expanding its royalty portfolio and navigating regulatory challenges.